Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227 Meeting Abstract
| Authors: | Schumann, C.; Paz-Ares, L.; Ciuleanu, T. E.; Lee, J. S.; Urban, L.; Caro, R. B.; Park, K.; Sakai, H.; Ohe, Y.; Nishio, M.; Pluzanski, A.; Ramalingam, S. S.; Brahmer, J. R.; Borghaei, H.; O'Byrne, K. J.; Hellmann, M. D.; Memaj, A.; Bushong, J.; Tran, P.; Reck, M. |
| Abstract Title: | Nivolumab (NIVO) plus ipilimumab (IPI) vs chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227 |
| Meeting Title: | Jahrestagung der Deutschen, Österreichischen und Schweizerischen Gesellschaften für Hämatologie und Medizinische Onkologie (Hybrid-Kongress) |
| Journal Title: | Oncology Research and Treatment |
| Volume: | 44 |
| Issue: | Suppl. 2 |
| Meeting Dates: | 2021 Oct 01-04 |
| Meeting Location: | Berlin, Germany |
| ISSN: | 2296-5270 |
| Publisher: | S. Karger AG |
| Date Published: | 2021-09-01 |
| Start Page: | 173 |
| Language: | English |
| ACCESSION: | WOS:000760622600317 |
| PROVIDER: | wos |
| DOI: | 10.1159/000518417 |
| Notes: | Meeting Abstract: ep161 "Joint Annual Meeting of the German, Austrian and Swiss Societies for Hematology and Medical Oncology (Hybrid Congress)" -- Meeting was also presented virtually -- Source: Wos |
